Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genomics-based cancer therapies developer Exelixis has achieved two milestones totaling $35 million under its collaboration agreement with healthcare titan GlaxoSmithKline.
Subscribe to our email newsletter
A patent appeals board had ruled in favor of Affymetrix, as did the U.S. District Court for the Northern District of California. But the U.S. Court of Appeals for the Federal Circuit, which hears patent appeals, ruled that the lower court had made a series of mistakes, and reversed the California court’s decision.
In addition, the appeals court also said that both the companies would bear its own costs.
The disputed invention focuses primarily upon the method of mixing the fluid for thorough contact with the microarray surface, the ruling said.